0.00%
-24.11%
-57.87%
-92.50%
-95.25%
-98.92%
-99.36%
AI Spotlight on ONCT
Create a Free
Company Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs.The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins.It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.
Oncternal Therapeutics, Inc.has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation.Oncternal Therapeutics, Inc.
has a research collaboration with Celularity Inc.to evaluate placental derived-cellular therapies targeting ROR1.The company is headquartered in San Diego, California.
Market Data
| Last Price | 0.53 |
| Change Percentage | -24.12% |
| Open | 0.7 |
| Previous Close | 0.69 |
| Market Cap ( Millions) | 2 |
| Volume | 644135 |
| Year High | 10.61 |
| Year Low | 0.53 |
| M A 50 | 0.53 |
| M A 200 | 3.8 |
Financial Ratios
| FCF Yield | -1708.77% |
| Dividend Yield | 0.00% |
| ROE | -177.58% |
| Debt / Equity | 2.09% |
| Net Debt / EBIDTA | 48.20% |
| Price To Book | 0.17 |
| Price Earnings Ratio | -0.05 |
| Price To FCF | -0.06 |
| Price To sales | 0.93 |
| EV / EBITDA | 0.42 |
News
- Aug -10 - Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript
- Aug -08 - Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates
- Aug -08 - Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
- Aug -01 - Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results
- Jul -11 - Oncternal Therapeutics to Present in JonesTrading Healthcare Summit
- May -30 - Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
- May -09 - Oncternal Therapeutics, Inc. (ONCT) Q1 2024 Earnings Call Transcript
- May -09 - Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates
- May -09 - Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
- May -08 - All You Need to Know About Oncternal Therapeutics (ONCT) Rating Upgrade to Buy
- May -02 - Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results
- May -01 - Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
- Apr -18 - Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
- Mar -15 - Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
- Mar -08 - Oncternal Therapeutics, Inc. (ONCT) Q4 2023 Earnings Call Transcript
- Mar -07 - Oncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue Estimates
- Mar -07 - Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
- Feb -29 - Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results
- Feb -06 - Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Feb -01 - Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Novel Oncology Therapies
Expected Growth : 10.93 %
What the company do ?
Oncternal Therapeutics, Inc.'s Novel Oncology Therapies involve developing innovative treatments, including cirmtuzumab, a ROR1-targeting monoclonal antibody, to combat various types of cancer.
Why we expect these perspectives ?
Oncternal Therapeutics' novel oncology therapies drive 10.93% growth, fueled by increasing cancer prevalence, advancements in gene editing and immunotherapy, and a growing demand for targeted treatments. Strong R&D investments, strategic partnerships, and a robust pipeline of innovative products also contribute to this growth.
Oncternal Therapeutics, Inc. Products
| Product Range | What is it ? |
|---|---|
| Cirmtuzumab | A monoclonal antibody that targets ROR1, a receptor that is highly expressed on certain types of cancer cells, including those in mantle cell lymphoma and chronic lymphocytic leukemia. |
| TK216 | A small molecule inhibitor of the ETS family of transcription factors, which are involved in the development and progression of certain types of cancer. |
| ONCT-808 | A CAR-T cell therapy that targets ROR1, a receptor that is highly expressed on certain types of cancer cells. |
| ONCT-534 | A small molecule inhibitor of the CDK2/4/6 pathway, which is involved in the regulation of cell cycle progression. |
Oncternal Therapeutics, Inc.'s Porter Forces
Threat Of Substitutes
Oncternal Therapeutics, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the biotechnology industry.
Bargaining Power Of Customers
Oncternal Therapeutics, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are specialized, making it difficult for customers to switch to alternative suppliers.
Bargaining Power Of Suppliers
Oncternal Therapeutics, Inc. relies on a few key suppliers for raw materials and services. While the company has some bargaining power due to its size, the suppliers also have some leverage due to the specialized nature of their products.
Threat Of New Entrants
The biotechnology industry is highly competitive, and new entrants can easily disrupt the market with innovative products and services. Oncternal Therapeutics, Inc. needs to continuously innovate and improve its products to stay ahead of the competition.
Intensity Of Rivalry
The biotechnology industry is highly competitive, and Oncternal Therapeutics, Inc. faces intense rivalry from established players and new entrants. The company needs to focus on differentiating its products and services to gain a competitive advantage.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 1.05% |
| Debt Cost | 3.95% |
| Equity Weight | 98.95% |
| Equity Cost | 10.74% |
| WACC | 10.67% |
| Leverage | 1.06% |
Oncternal Therapeutics, Inc. : Quality Control
Oncternal Therapeutics, Inc. passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CSBR | Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach … |
| DNTH | Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that … |
| TCRX | TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment … |
| KYMR | Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It … |
| TARS | Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Champions Oncology
A-Score
1-Year Total Return ->
🥈
Tarsus Pharmaceuticals
A-Score
1-Year Total Return ->
🥉
Kymera Therapeutics
A-Score
1-Year Total Return ->
4
Dianthus Therapeutics
A-Score
1-Year Total Return ->
5
Oncternal Therapeutics
A-Score
1-Year Total Return ->
6
